Advertisement

U.S. Markets closed

S&P Futures
5,888.25
-4.25(-0.07%)
Dow Futures
43,045.00
-124.00(-0.29%)
Nasdaq Futures
20,520.00
-22.00(-0.11%)
Russell 2000 Futures
2,244.80
-1.40(-0.06%)
Crude Oil
72.24
+0.15(+0.21%)
Gold
2,753.00
-6.80(-0.25%)

Caribou Biosciences, Inc. (CRBU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

1.9800

+0.0100

(+0.51%)

At close: 04:00PM EDT

1.9500

-0.03

(-1.52%)

After hours:

05:50PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024
BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract has been accepted for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024, which will be held November 14-19, 2024 in Washington, DC. The poster will highlight the preclinical data and key elements of the clinical trial design that supported the investigational new drug
Simply Wall St.
With 60% ownership, Caribou Biosciences, Inc. (NASDAQ:CRBU) boasts of strong institutional backing
Key Insights Given the large stake in the stock by institutions, Caribou Biosciences' stock price might be vulnerable...